Navigation Links
Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Date:9/14/2011

the subjects maintained positive CD8+ T-cell responses out to six months.
  • Compared to the previously conducted HVTN 070 Phase I study, which assessed PENNVAX™-B with cytokine adjuvant IL-12 at double the dose, with four vaccinations, but without electroporation delivery, response rates in HVTN 080 with electroporation were significantly higher for both CD4+ responses (40.7%) and CD8+ T cell responses (3.6%).
  • Samples from eight placebo recipients and pre-vaccine samples from vaccine recipients were also tested and were negative for both CD4+ T-cell responses and CD8+ T-cell responses.
  • PENNVAX™-B delivered using the CELLECTRA® intramuscular electroporation delivery device with or without IL-12 was safe and generally well tolerated. There were no vaccine-related serious adverse events. Reported adverse events and injection site reactions were mild to moderate and required no treatment.

  • Dr. J. Joseph Kim, Inovio's President and CEO, said: "We are excited by the final results of the HVTN-080 study. These data are consistent with the previously announced interim results and unequivocally demonstrate the impact electroporation has on improving the immune potency of DNA vaccination. We appreciate the close collaboration with the NIH DAIDS and HVTN groups to systematically evaluate the immunogenicity of DNA immunogens together with cytokine adjuvants and delivery systems. We look forward to a continuing fruitful partnership with the HVTN and the DAIDS/NIH to further develop our HIV vaccine products to the next level."

    About the HVTNThe HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, Wash., is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The HVTN's mission is to facilitate the process of testing preventive vaccines against HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating
    '/>"/>

    SOURCE Inovio Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
    2. Inovio Pharmaceuticals to Present at Investor Conferences
    3. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
    4. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
    5. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
    6. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
    7. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
    8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
    9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
    10. Inovio Pharmaceuticals to Present at Investor Conferences
    11. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... 30, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, has recently released a ... is a topical liquid tetracycline-based antibiotic that uses ... convert oral medication active ingredients into topical drugs. ... aid antibiotic to help prevent skin infection in ...
    (Date:10/30/2014)... 30, 2014 CVS Health (NYSE: CVS ... with three leading regional health systems to enhance access to ... systems include Baptist Health System in Alabama ... Health in Pennsylvania , Northwest Medical Center, ... and Tennova Healthcare in Tennessee ; and ...
    (Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
    Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
    ... Nordisk Inc., a global healthcare company and leader in diabetes care, today ... information on diabetes and chronic disease, highlighting key issues in diabetes prevention, ... , ... evolved over the last 90 years, how it is developed today, the ...
    ... NEW ORLEANS , July 12 Proventix Systems, Inc., of ... Alabama -based technology company, that will help them fight the spread ... , , , , ... in Infection Control and Epidemiology, HAIs contribute $28 billion to $33 ...
    Cached Medicine Technology:Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease 2Proventix™ Partners with Synapse Wireless to Save Lives 2Proventix™ Partners with Synapse Wireless to Save Lives 3
    (Date:10/30/2014)... PreDiabetes Centers , the pioneer in ... with a supply of sugardown®, a chewable dietary supplement ... sugar spikes. Learning how to control blood sugar levels ... a diabetes prevention plan. , Shoppers who spend $50 ... of sugardown. The offer expires November 30. , ...
    (Date:10/30/2014)... By Tara Haelle ... (HealthDay News) -- More than 100 genes have been ... new studies report. And researchers say they are ... overall that may contribute to the disorder. Autism ... by communication and social difficulties and repetitive behaviors. An ...
    (Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
    (Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
    (Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
    Breaking Medicine News(10 mins):Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Women Often Ignore Signs of Heart Trouble 2
    ... past have argued about the implications of Hormone Replacement Therapy ... A new study, however, has gone further to show that ... developing breast cancer// if they consumed alcoholic beverages. ,The ... pattern and on whether they were on HRT currently or ...
    ... have found that people who take anti-depressants to relieve ... developing gastrointestinal bleeding. The study which was conducted over ... were compared for hospitalizations due to upper GI bleeding ... on selective serotonin reuptake inhibitors, or SSRIs, were 3.6-times ...
    ... by a Diabetes Research Centre in India has shown that ... had considerable improvement when they followed safe practices advised by ... doctors discovering that many patients came to the Centre with ... their lives. They decided that a little change in lifestyle ...
    ... called 'HERS' conducted by researchers of the University of California, ... that Hormone Replacement Therapy (HRT) may be able to reduce ... develop diabetes as well. ,The study involved some women ... had "impaired fasting glucose" - a condition with some ...
    ... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
    ... Chairman and Managing Director of Eli Lilly and Co., India, ... cut in the company's human insulin product 'Huminsulin', that its ... market by the end of this year. He added that ... use of human insulin products and the phasing out of ...
    Cached Medicine News:Health News:Women on HRT should avoid alcohol 2
    ... Dynal RELI™ SSO typing technique utilises a ... flank the specific target region of an ... of the resulting amplicon to an array ... a nylon membrane. The immobilisation of these ...
    ... The Reichert UNISTAT ... photometric analyzer for determining ... newborn infants. It quickly ... tests are needed by ...
    Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
    ... Follicle-Stimulating Hormone (FSH) is a glygoprotein produced by ... as LH, TSH, and HCG, FSH consists of ... is a solid phase direct sandwich ELISA method. ... to the wells coated with Mab to FSH ...
    Medicine Products: